Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Posttransplantation: future therapies.

M G Peters¹, D Shouval, A Bonham

¹University of California at San Francisco, USA.

Seminars in Liver Disease

|July 15, 2000

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Retraction Note: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways.

Breast cancer research and treatment·2023

Same author

Duodenal Permeability Is Associated With Mucosal Microbiota in Compensated Cirrhosis.

Clinical and translational gastroenterology·2022

Same author

[Proper patient education improves hepatitis C patients' disease-related knowledge and antiviral treatment acceptance in rural China].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology·2019

Same author

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Alimentary pharmacology & therapeutics·2018

Same author

The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease.

Alimentary pharmacology & therapeutics·2017

Same author

Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment.

Journal of viral hepatitis·2017

Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026

Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026

Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026

Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026

Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026

Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026

See all related articles

Preventing hepatitis B virus (HBV) recurrence after liver transplant is crucial. New strategies beyond current expensive therapies like hepatitis B immune globulin (HBIG) are needed to improve outcomes and reduce breakthrough infections.

Area of Science:

Hepatology
Virology
Transplantation Immunology

Background:

Hepatitis B virus (HBV) recurrence post-liver transplantation remains a significant clinical challenge.
Current prophylaxis with hepatitis B immune globulin (HBIG) and nucleoside analogues are effective but costly and prone to breakthrough infections from resistant mutants.
Improved outcomes in liver transplantation for hepatitis B necessitate novel prevention and treatment strategies.

Purpose of the Study:

To explore new strategies for preventing and treating hepatitis B virus (HBV) recurrence after liver transplantation.
To address the limitations of current therapies, including cost and the emergence of resistant HBV strains.
To enhance the cost-effectiveness of liver transplantation for hepatitis B patients.

Main Methods:

Related Experiment Videos

Review of current prophylaxis and treatment strategies for HBV recurrence.
Exploration of novel therapeutic approaches including vaccination, adoptive immunotherapy (bone marrow, T-cell, xenotransplantation), and gene therapy.
Analysis of nucleoside and nucleotide analogues targeting the HBV life cycle.
Evaluation of combination therapies involving HBIG and new antiviral agents.

Main Results:

Vaccination is recommended pre-transplant but shows reduced efficacy in immunosuppressed patients.
Adoptive transfer of immunity and gene therapies show potential for preventing or treating recurrent HBV.
Nucleoside/nucleotide analogues can disrupt HBV replication and assembly.
Combination therapy is likely essential for optimal prevention of HBV recurrence.

Conclusions:

Current HBIG and nucleoside analogue therapies for HBV post-liver transplant have limitations.
Emerging strategies like immunotherapy, gene therapy, and novel antivirals offer promising alternatives.
A combination approach, integrating HBIG with new antiviral agents, is anticipated to be the most effective strategy for preventing recurrent hepatitis B.